Narcan Now Available Over the Counter to Reverse Opioid Overdoses
Narcan, the trade name for Naloxone HCl Nasal Spray, was approved for over-the-counter (OTC) nonprescription use by the U.S. Food and Drug Administration in March, becoming the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose.
Emergent BioSolutions has announced that shipments of its over the counter, original prescription strength NARCAN® Nasal Spray 4mg are now being delivered to leading pharmacies and grocery stores, as well as online retailers.
Drug overdose persists as a major public health issue in the United States, with more than 101,750 reported fatal overdoses occurring in the 12-month period ending in October 2022, primarily driven by synthetic opioids like illicit fentanyl. Construction workers account for nearly 23% of all opioid overdose deaths. Many of these happened on the job.
When someone is having an opioid overdose, the receptors in their brain get filled and overstimulated by opioids and when these receptors are full or are “maxed out,” your brain tells your body to slow down or even stop your breathing. Naloxone works to reverse this process. It works by binding with and blocking opioid receptors to rapidly reverse the effects of opioid overdose.
According to Emergent, last year, approximately every seven minutes one life was lost due to an opioid overdose, and today it is the leading cause of accidental death in the United States. The average response time for emergency services to arrive is approximately 10 minutes.
Having NARCAN® Nasal Spray in a first-aid kit on a job site, or carrying it on the go in case of an opioid emergency, can make a difference and help reverse the effects of opioids while waiting for emergency personnel to arrive.
The manufacturer’s suggested retail price of NARCAN® Nasal Spray is $44.99 per two-dose carton, roughly $22.50 per dose.
Learn more about Naloxone. NAHB also has resources to address the opioid crisis in construction.
Latest from NAHBNow
Economics
Jul 16, 2026
Builder Sentiment Stays Weak as Affordability Concerns PersistEconomic uncertainty and persistent affordability challenges driven by rising material prices, high land costs, and elevated mortgage rates continue to weigh on builder sentiment.
Membership
Jul 15, 2026
New Issue of Building Women Magazine Is Now AvailableThe latest edition of Building Women Magazine showcases career paths for women in the residential building industry, including 2026 Professional Women in Building (PWB) Chair Heather Laminack.
Latest Economic News
Economics
Jul 16, 2026
Builder Sentiment Stays Weak as Affordability Concerns PersistEconomic uncertainty and persistent affordability challenges driven by rising material prices, high land costs, and elevated mortgage rates continue to weigh on builder sentiment.
Economics
Jul 15, 2026
Building Material Prices Continue to Rise Despite Energy Price DeclinesResidential building material prices, excluding energy, rose 0.5% in June and were up 4.6% from a year ago. Lower energy prices were apparent in June, as energy input prices fell 10.3% over the month. Meanwhile, prices for services rose 5.2% over the year, and were up 1.0% from the previous month.
Economics
Jul 15, 2026
Single-Family Permitting Continued to Weaken Through MayState-level permitting activity continued to reflect a divided housing market through the first five months of 2026. Elevated mortgage rates and ongoing affordability challenges continued to weigh on single-family construction across much of the country, while multifamily permitting remained comparatively stronger, supported by gains in several regions despite continued weakness in parts of the South.